DNA Sequencing Market Will Exceed $20 Billion, Says Illumina CEO

Illumina ILMN +1.2%, one of the most important companies in biomedicine, is still barely known to the public. But scientists, diagnostics makers, physicians, and Wall Street look at the company with a mix of fear and awe. Just as Intel INTC -0.42% became the company that sparked so much of the computer revolution, Illumina has risen to prominence as a driver of the genomics revolution.

The San Diego-based company makes the workhorse machines that sequence genomes—the full set of genetic instructions for making bacteria, plants, animals, and humans. The decoding tools run around the clock in academic labs all over the world. As researchers race to develop DNA-based technologies that detect genetic abnormalities in developing fetuses, variations that drive tumors, and much more, Illumina shows no signs of letting up.

Hey, check out all the research scientist jobs. Post your resume today!

MORE ON THIS TOPIC